Bictegravir-Tenofovir alafenamide-Emtricitabine ( Biktarvy ) - PowerPoint PPT Presentation

Bictegravir-Tenofovir alafenamide-Emtricitabine ( Biktarvy ) Prepared by: Brian R. Wood, MD David H. Spach, MD Last Updated: December 31, 2019

Bictegravir-Tenofovir Alafenamide-Emtricitabine ( Biktarvy) Biktarvy [bik-TAR-vee] Bictegravir-Tenofovir alafenamide-Emtricitabine 50 mg 25 mg 200 mg INSTI NRTI NRTI Dose: 1 tablet once daily with or without food

Bictegravir-Tenofovir alafenamide-Emtricitabine ( Biktarvy ) • Single-Tablet Regimen Components : Bictegravir: 50 mg Tenofovir alafenamide: 25 mg Emtricitabine: 200 mg • Dosing : 1 pill daily with or without food • With Renal or Hepatic Impairment - Do not initiate if estimated CrCl <30 mL/min - Do not initiate with severe hepatic impairment (Child-Pugh C) • Pregnancy : insufficient data • Common Adverse Events (≥5%) - Diarrhea (6%), nausea (5%), and headache (5%)

Bictegravir-Tenofovir alafenamide-Emtricitabine Summary of Key Studies • Phase 2 Trial in Treatment-Naïve Adults - GS-141-1475: BIC + TAF-FTC versus DTG + TAF-FTC • Phase 3 Trials in in Treatment-Naïve Adults - GS-380-1489: BIC-TAF-FTC versus DTG-ABC-3TC - GS-380-1490: BIC-TAF-FTC versus DTG + TAF-FTC • Phase 3 Trials in Adults with Virologic Suppression - GS-380-1844: Switch to BIC-TAF-FTC or stay on DTG-ABC-3TC - GS-380-1878: Switch to BIC-TAF-FTC or stay on boosted PI + NRTIs - GS-380-1844: 1961: Switch to BIC-TAF-FTC in women - GS-380-1844 and GS-380-1878: Impact of Archived M184V Mutation

INITIAL THERAPY Bictegravir-Tenofovir alafenamide-Emtricitabine

Bictegravir versus Dolutegravir, each with TAF-FTC GS-141-1475

Bictegravir versus Dolutegravir, each with TAF-FTC GS-141-1475: Design GS-141-1475: Study Design • Background : Randomized, double-blind, placebo- controlled, phase 2 study evaluating the efficacy and safety of bictegravir versus dolutegravir as Bictegravir 75 mg QD part of antiretroviral therapy for treatment-naïve + TAF-FTC adults with HIV (n = 65) • Inclusion Criteria - Age > 18 - Antiretroviral-naïve - CD4 count >200 cells/mm 3 Dolutegravir 50 mg QD - HIV RNA ≥1,000 copies/mL + TAF-FTC - eGFR >70 mL/min (n = 33) - Genotypic sensitivity to TAF and FTC - No hepatitis B or C - Not pregnant - No AIDS-defining condition within 30 days Source: Sax PE, et al. Lancet HIV. 2017;4:e154-e160.

Bictegravir versus Dolutegravir, each with TAF-FTC GS-141-1475: Results Weeks 24 and 48: Virologic Response by FDA Snapshot Analysis Bictegravir + TAF-FTC Dolutegravir + TAF-FTC 100 HIV RNA < 50 copies/mL (%) 97 97 94 91 80 60 40 20 63/65 31/33 63/65 30/33 0 24 weeks 48 weeks Source: Sax PE, et al. Lancet HIV. 2017;4:e154-e160.

Bictegravir versus Dolutegravir, each with TAF-FTC GS-141-1475: Adverse Events Most Frequent Adverse Events in Either Study Group Bictegravir + TAF-FTC Dolutegravir + TAF-FTC (n = 65) (n = 33) Any adverse event 55 (85%) 22 (67%) Diarrhea 8 (12%) 4 (12%) Nausea 5 (8%) 4 (12%) Arthralgia 4 (6%) 2 (6%) Fatigue 4 (6%) 2 (6%) Headache 5 (8%) 1 (3%) No serious treatment-related adverse events occurred in either arm. 1 participant (with history of atopic dermatitis) in the bictegravir arm discontinued due to urticaria. Source: Sax PE, et al. Lancet HIV. 2017;4:e154-e160.

Bictegravir versus Dolutegravir, each with TAF-FTC GS-141-1475: Laboratory Abnormalities Most frequent laboratory abnormalities in either study group Bictegravir + TAF-FTC Dolutegravir + TAF-FTC (n = 65) (n = 33) Any laboratory abnormality 28 (44%) 15 (47%) Creatinine kinase elevation 8 (13%) 3 (9%) AST elevation 6 (9%) 1 (3%) Fasting glucose elevation 5 (8%) 4 (13%) ALT elevation 4 (6%) 0 (0%) LDL elevation 4 (6%) 3 (9%) Amylase elevation 3 (5%) 2 (6%) Median decrease from baseline in estimated creatinine clearance: 7.0 mL/min in the bictegravir arm and 11.3 mL/min in the dolutegravir arm. Source: Sax PE, et al. Lancet HIV. 2017;4:e154-e160.

Bictegravir versus Dolutegravir, each with TAF-FTC GS-141-1475: Virologic Rebound and Resistance Participants with Viral Rebound Meeting Protocol-Defined Criteria for Genotype Resistance Testing Study arm Resistance detected Participant 1 Bictegravir + TAF-FTC None Participant 2 Dolutegravir + TAF-FTC None Participant 3* Dolutegravir + TAF-FTC T97A *This participant discontinued the study at week 48 due to non-adherence. Source: Sax PE, et al. Lancet HIV. 2017;4:e154-e160.

Bictegravir versus Dolutegravir, each with TAF-FTC GS-141-1475: Conclusions Interpretation : “ Bictegravir plus emtricitabine and tenofovir alafenamide and dolutegravir plus emtricitabine and tenofovir alafenamide both showed high efficacy up to 24 weeks. Both treatments were well tolerated. Administration of bictegravir, a novel, potent, once-daily INSTI designed to improve on existing INSTI options with the backbone of emtricitabine and tenofovir alafenamide, might provide an advantage to patients .” Source: Sax PE, et al. Lancet HIV. 2017;4:e154-e160.

BIC-TAF-FTC vs. DTG-ABC-3TC as Initial Therapy GS-380-1489

BIC-TAF-FTC versus DTG-ABC-3TC as Initial Therapy GS-380-1489: Design GS-380-1489: Study Design • Background : Randomized, double-blind, active- controlled, phase 3 study evaluating the efficacy and safety of bictegravir-tenofovir alafenamide- emtricitabine versus dolutegravir-abacavir- Bictegravir-TAF-FTC lamivudine for treatment-naïve adults with HIV (n = 314) • Inclusion Criteria - Age >18 - Antiretroviral-naïve (or ≤10 days of treatment) - HIV RNA ≥500 copies/mL - eGFR ≥50 mL/min Dolutegravir-ABC-3TC - HLA B*5701 negative (n = 315) - No chronic HBV infection • Regimens - Bictegravir-TAF-FTC (50/25/200 mg) - Dolutegravir-ABC-3TC (50/600/300 mg) Source: Gallant J, et al. Lancet. 2017;390:2063-72.

BIC-TAF-FTC versus DTG-ABC-3TC as Initial Therapy GS-380-1489: Baseline Characteristics Study GS-380-1489 Baseline Characteristics BIC-TAF-FTC DTG + TAF-FTC Characteristic (n = 314) (n = 315) 31 (18-71) 32 (18-68) Median age, years (range) 91 90 Male, % 36 36 Black or African descent, % 17 16 HIV RNA >100,000 copies/mL, % 11 10 CD4 count <200 cells/mm 3 , % 125.9 123.0 Median CrCl, mL/min Abbreviations: CrCl = creatinine clearance Source: Gallant J, et al. Lancet. 2017;390:2063-72.

BIC-TAF-FTC versus DTG-ABC-3TC as Initial Therapy GS-380-1489: Results Week 48 Virologic Response (Intention-to-Treat Analysis) Bictegravir-TAF-FTC Dolutegravir-ABC-3TC 100 HIV RNA <50 copies/mL (%) 93.0 92.4 80 60 40 20 290/314 293/315 0 No treatment-emergent resistance to any study drug occurred Source: Gallant J, et al. Lancet. 2017;390:2063-72.

BIC-TAF-FTC versus DTG-ABC-3TC as Initial Therapy GS-380-1489: Adverse Events Treatment Emergent Adverse Events (AE’s >5%) Through Week 48 BIC-TAF-FTC DTG-ABC-3TC (n = 314) (n = 315) Diarrhea, % 13 13 Headache, % 11 14 Nausea, % 10 23 Fatigue, % 6 9 Arthralgia, % 4 6 Insomnia, % 4 6 Change in eGFR (mL/min) -10.5 -10.8 Source: Gallant J, et al. Lancet. 2017;390:2063-72.

BIC-TAF-FTC versus DTG-ABC-3TC for Initial Therapy GS-380-1489: Results Change in Markers of Proximal Tubulopathy at 48 Weeks Bictegravir-TAF-FTC Dolutegravir-ABC-3TC 30 Median % Change from Baseline 19.9 20 13.6 10 6.2 0.6 0 -10 -20 -18.1 -23.0 -30 Urine Albumin/ Retinonl Binding Beta-2-Microglobulin/ Creatinine Protein Creatinine Source: Gallant J, et al. Lancet. 2017;390:2063-72.

BIC-TAF-FTC versus DTG-ABC-3TC for Initial Therapy GS-380-1489: Results Change in Bone Mineral Density at 48 Weeks Bictegravir-TAF-FTC Dolutegravir-ABC-3TC 0.5 Median % Change from Baseline 0.0 -0.5 -0.60 -0.78 -0.83 -1.0 -1.02 -1.5 Spine Hip Source: Gallant J, et al. Lancet. 2017;390:2063-72.

BIC-TAF-FTC versus DTG-ABC-3TC for Initial Therapy GS-380-1489: Results Change in Lipids at 48 Weeks Bictegravir-TAF-FTC Dolutegravir-ABC-3TC Median Change from Baseline 20 15 13 (mg/dL) 11 10 9 7 5 5 5 4 3 0 TC LDL HDL TG Source: Gallant J, et al. Lancet. 2017;390:2063-72.

BIC-TAF-FTC versus DTG-ABC-3TC for Initial Therapy GS-380-1489: Conclusions Interpretation : “ At 48 weeks, coformulated bictegravir, emtricitabine, and tenofovir alafenamide achieved virological suppression in 92% of previously untreated adults and was non-inferior to coformulated dolutegravir, abacavir, and lamivudine, with no treatment-emergent resistance. Bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated with better gastrointestinal tolerability than dolutegravir, abacavir, and lamivudine. Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide does not require HLA B*5701 testing and provides guideline-recommended treatment for individuals co-infected with HIV and hepatitis B, this regimen might lend itself to rapid or same- day initiation of therapy in the clinical setting.” Source: Gallant J, et al. Lancet. 2017;390:2063-72.

BIC-TAF-FTC vs. DTG + TAF-FTC as Initial Therapy GS-380-1490: Week 48 Results